Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis

Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis

IntroductionThis meta-analysis aims to compare the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy in comparison to bismuth-containing quadruple therapy (BQT) for patients with Helicobacter pylori (H. pylori) infection.Materials and methodsFour databases (PubMed, Embase, Web of Scien...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiao Li, Cheng Jiang, Yuwen Su, Ruiyun Gao, Peijun Yang, Yuechen Qin, Yue Zou, Weiming Liang, Jieru Quan, Liying Pan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Microbiology
Subjects:	H. pylori amoxicillin vonoprazan eradication bismuth-containing quadruple therapy compliance
Online Access:	https://www.frontiersin.org/articles/10.3389/fmicb.2025.1561749/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker– and Proton Pump Inhibitor–Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Network Meta-Analysis
by: Iqbal Taufiqqurrachman, et al.
Published: (2025-01-01)

Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence
by: Qiyunna He, et al.
Published: (2024-05-01)

Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of Helicobacter pylori infection with vonoprazan amoxicillin: a prospective, multicenter, randomized controlled trial
by: Yunfan Dong, et al.
Published: (2025-03-01)

Efficacy and Safety of 10‐Day Versus 14‐Day Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis
by: Najam Gohar, et al.
Published: (2025-03-01)

Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori
by: Jing Yu, et al.
Published: (2024-11-01)

Tegoprazan dual and quadruple therapy for Helicobacter pylori eradication: a prospective, randomized controlled trial in Beijing, China
by: Jianping Cheng, et al.
Published: (2025-08-01)

Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobacter pylori eradication
by: Yi-Zhou Jiang, et al.
Published: (2025-04-01)

Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-Line <i>Helicobacter pylori</i> Eradication Using Tegoprazan, Clarithromycin, and Bismuth: A Propensity Score Matching Analysis
by: Jun-Hyung Cho, et al.
Published: (2024-09-01)

Eradication of Helicobacter pylori: a prospective comparative randomized trial of standard versus optimized quadruple therapy
by: Salma Souissi, et al.
Published: (2024-12-01)

Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: an open-label randomized controlled trial
by: Yumna M. Shekeban, et al.
Published: (2025-05-01)

First‐Line Levofloxacin‐Based Triple Therapy Versus Standard Bismuth‐Based Quadruple Therapy for Helicobacter pylori Eradication in Saudi Arabia: A Retrospective Single‐Center Study
by: Abdulrhman Khaled Al Abdulqader, et al.
Published: (2025-02-01)

High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection – A review of the strengths, weaknesses, and proposed solutions
by: Chi-Tan Hu
Published: (2022-01-01)

Fecal microbiota transplantation from Helicobacter pylori carriers following bismuth quadruple therapy exacerbates alcohol-related liver disease in mice via LPS-induced activation of hepatic TLR4/NF-κB/NLRP3 signaling
by: Huihui Gao, et al.
Published: (2025-06-01)

A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis
by: Sung Eun Kim, et al.
Published: (2021-03-01)

A Randomized, Prospective and Crossover Study, Comparing the Eradication Rate After 10 Days of Concomitant Therapy to Bismuth Quadruple Therapy Among a Sample of the Lebanese Population
by: Jad Chidiac, MD, et al.
Published: (2025-01-01)

Rational choice of eradication therapy of <i>Helicobacter pylori</i> infection
by: T. L. Lapina, et al.
Published: (2013-10-01)

Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-Line <i>Helicobacter pylori</i> Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Jun-Hyung Cho, et al.
Published: (2025-02-01)

Efficiency of ursodeoxycholic acid in the frameworks of minimization of hepatotoxic potential of eradication therapy of Helicobacter pylori infection
by: D. N. Andreev, et al.
Published: (2021-06-01)

The importance of bismuth-containing quadruple therapy in Helicobacter pylori eradication in an era of increasing antibiotic resistance
by: Yi HU, et al.
Published: (2020-06-01)

Randomized multicenter trial comparing minocycline and ornidazole with classical quadruple therapy in Helicobacter pylori treatment
by: Yi Lin, et al.
Published: (2025-05-01)

The efficacy of quadruple therapy in non-ulcer Helicobacter Pylory gastritis in children: A prospective study
by: Hien Thi Phan, et al.
Published: (2025-01-01)

Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trial
by: William D Chey, et al.
Published: (2024-11-01)

The role of probiotic supplementation in reducing Helicobacter pylori recurrence after classic quadruple therapy
by: Jie Zhao, et al.
Published: (2025-07-01)

Bismuth-containing drugs in clinical practice in the XXI century - history or a new round of possibilities?
by: V. A. Akhmedov
Published: (2024-09-01)

Tailored Therapy Using Bismuth Add-on Standard Triple Therapy vs. Concomitant Therapy: A First-line Regimen for Helicobacter pylori Infection
by: Soo Yeon Choi, et al.
Published: (2023-06-01)

Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Eradication
by: Hyun Soo Kim, et al.
Published: (2020-09-01)

Efficacy and safety of tetracycline vs. amoxicillin in furazolidone-based rescue therapy for Helicobacter pylori: a real-world analysis
by: Jinliang Xie, et al.
Published: (2025-12-01)

Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for treatment: a randomized clinical trial
by: Jin-Yan Zhang, et al.
Published: (2025-07-01)

Macrophage Membrane-Coated Liposomes Delivering Vonoprazan Disrupt Mitochondrial Oxidative Phosphorylation in Diffuse Large B-Cell Lymphoma
by: Wang W, et al.
Published: (2025-06-01)

Efficacy and safety of nitazoxanide based quadruple regimen as first line therapy for treating Helicobacter pylori infected naïve patients
by: Amro M Hassan, et al.
Published: (2025-06-01)

First-Line Prescriptions and Effectiveness of <i>Helicobacter pylori</i> Eradication Treatment in Ireland over a 10-Year Period: Data from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)
by: Sinéad M. Smith, et al.
Published: (2025-07-01)

Post-marketing stability surveillance: Amoxicillin
by: K.K. Naidoo, et al.
Published: (2006-07-01)

Clinical efficacy of acupoint application therapy combined with Kangyou Decoction in treating Helicobacter pylori infection with damp-heat syndrome of the middle Jiao
by: Shang-Ren Xie, et al.
Published: (2025-08-01)

Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for <i>Helicobacter pylori</i> Infection: A Systematic Review
by: Chih-An Shih, et al.
Published: (2025-03-01)

Potential Unnecessity of Bismuth in Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori Infection
by: Seon Woo Oh, et al.
Published: (2025-03-01)

Quadruple coincidence and common quadruple fixed point for hybrid pair of mappings under new contractive condition
by: Deshpande Bhavana, et al.
Published: (2014-01-01)

On the issue of adjuvant therapy of <i>Helicobacter pylori</i> infection: focus on probiotics and prebiotics. A review
by: Natalia V. Baryshnikova, et al.
Published: (2025-01-01)

Bismuth-Based Quadruple Therapy with Bismuth Subcitrate, Metronidazole, Tetracycline and Omeprazole in the Eradication of Helicobacter pylori
by: Raymond Lahaie, et al.
Published: (2001-01-01)

Vonoprazan–minocycline dual therapy as a first-line treatment of infection compared with empirical bismuth-containing quadruple therapy
by: Meng Li, et al.
Published: (2025-08-01)

Estimation of cytoprotective effect of bismuth tripotassium dicitrate on gastric mucosa at <i>H. pylori</i> eradication and long-term drug intake
by: A. V. Kononov, et al.
Published: (2014-12-01)